Brett P Monia

Ionis CEO Brett P Monia sells 85,637 shares for $6.8M under pre-arranged 10b5-1 plan (2026-06-24 to 2026-06-26)

Brett P Monia executed 3 separate sales totaling 85,637 shares for $6,825,523.71 on 2026-06-24 through 2026-06-26, reducing non-derivative holdings from 331,208 to 245,571 shares (-25.9% of pre-transaction holdings). The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, meaning this is a scheduled, non-discretionary transaction sequence rather than a discretionary market decision. At the time of sale, the stock traded in the range of $78.41–$80.59 (blended average $79.70); the current price is $81.18, reflecting minimal divergence from the execution prices. While the CEO retains 245,571 non-derivative shares post-transaction, significant derivative holdings totaling 120,944 shares in non-qualified stock options remain outstanding, preserving material ongoing equity exposure. The company is unprofitable (net income of -$92,528,000.00 over the most recent full fiscal year) but has grown revenue at +33.8% annually.

Monia Brett P (CEO) sold 160.8K shares for $12.1M across 5 transactions in March 2026; stock down 11.8% in 30 days post-sale.

Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals, executed 5 separate sales totaling 160,773 shares for $12,114,155.19 at blended average price of $75.35 on March 9–10, 2026. This represents a 39.9% reduction in her pre-transaction holdings of 403,435 shares, leaving post-transaction holdings of 242,662 shares. The timing is notable: the stock has declined 11.8% in the 30 days since the sale and is currently trading at $74.79, down 13.5% from its 52-week high of $86.50. The CEO's prior trades at Ionis show mixed outcomes—two completed 90-day periods both posted positive returns (+33.2% and +35.2%), meaning those prior sales were poorly timed relative to subsequent stock performance. Ionis is currently unprofitable (annual net income negative at $-128,606,000.00) despite 33.8% annual revenue growth, a fundamental context that may contextualize the magnitude of this substantial position reduction.

CEO Monia Brett P sold 29,430 shares of IONS at $85.79 on 2026-02-06 for $2,524,820.30.

Monia Brett P, CEO of Ionis Pharmaceuticals, sold 29,430 shares at $85.79, reducing holdings by 10.4% while the stock trades -2.6% from its 52-week high of $86.50. His prior trades at IONS show a concerning timing pattern: three measured sales from September 2025 all resulted in positive 90-day returns (+13.2% to +17.0%), meaning the stock rose substantially after each sale—0 of 3 were well-timed for a shareholder seeking to exit before declines. Against this backdrop, the company reported a negative $128,606,000.00 net income in its latest quarter and annual revenue decline of -10.5%, indicating ongoing operational challenges despite recent stock strength. The recent sales cluster (January 30, January 16, and now February 6) warrants monitoring to determine whether this represents a pattern shift or if measurable outcomes follow the prior poorly-timed pattern.

CEO Monia Brett P sold 62,970 shares of IONS at $82.72 on 2026-01-30 ($5.2M); stock near 52-week high, unprofitable company declining revenue.

Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals, executed a significant sale of 62,970 shares at $82.72, representing an 18.2% reduction in holdings from 346,897 to 283,927 shares. The transaction occurred near the stock's 52-week high of $83.88 (within 1.0% of peak), with the stock up 4.3% over the prior 30 days and 14.0% over 90 days. However, the underlying fundamentals present a contrasting picture: the company generated $156.7M in revenue last quarter while posting a net loss of $128.6M, with annual revenue declining 10.5% year-over-year and full-year net income negative. Prior sales by this insider at IONS have consistently failed to precede declines—all 4 measurable same-ticker sales showed positive 90-day returns (ranging from 6.3% to 37.5%), indicating poorly-timed exits relative to subsequent price action. This sale's timing near a 52-week peak against a backdrop of declining revenue and persistent unprofitability warrants close monitoring of company fundamentals and insider confidence signals.

CEO Brett P sells 44,034 shares of IONS at $74.82 (Jan 2026); current price $77.53, stock near 52-wk high despite -10.5% revenue decline.

Monia Brett P, as Chief Executive Officer, sold 44,034 shares at $74.82 on 2026-01-16, reducing his holdings by 16.4% to 224,683 shares post-transaction. At the current price of $77.53, the stock trades above his sale price and near the top of its 52-week range ($25.51–$83.17), suggesting he sold before a material move upward or at least before market momentum changed in the stock's favor. However, context is critical: IONIS reported revenue of $156,719,000.00 in the latest quarter with a net loss of $128,606,000.00, and annual revenue declined 10.5% year-over-year, indicating operational headwinds. His same-ticker history at IONS shows mixed timing: three prior sales in September 2025 yielded strong subsequent gains (90d returns of +33.2%, +35.2%, +37.5%), but a January 2025 sale resulted in a -13.1% 90d decline—well-timed—suggesting variability in his execution at this ticker. The current sale occurs as the stock sits within normal trading range post its 52-week high, with no clear pattern indicating conviction or concern based on timing alone.

Monia Brett P (CEO) sold 203,814 shares for $12,294,703.01 (3 transactions), reducing stake by 53.1%

CEO Monia Brett P executed 3 separate sales on 2025-09-03 totaling 203,814 shares for $12,294,703.01 at a blended average price of $60.32, reducing her holdings from 383,823 shares to 180,009 shares—a 53.1% reduction. The sale occurred as IONS stock trades near its 52-week high of $60.49, having appreciated 37.9% over 30 days and 68.2% over 90 days from prior lows. At the same-ticker level, her prior 5 sales show that 4 of 5 were well-timed at the 90-day mark (stock declined after the sale), establishing a consistent pattern of exiting before downturns, though the current transaction's forward timing cannot be assessed immediately. Notably, the company reported full-year net income was negative despite a $123.6M net income in the latest quarter, and annual revenue contracted 10.5% year-over-year, creating fundamental tension between near-term profitability and longer-term revenue pressure.

Monia Brett P (CEO) sold 38,843 shares of IONS at $31.65; stock down -37.1% from 52-week high, unprofitable despite 34.1% revenue growth

Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals, sold 38,843 shares at $31.65 on 2025-02-04, representing a -17.7% reduction in her holdings (from 219,526 to 180,683 shares). The sale comes as the stock has declined -37.1% from its 52-week high and stands -6.7% lower over the past 30 days; notably, her four prior measurable sales at IONS were all well-timed at the 90-day mark. However, the company faces a structural headwind: despite annual revenue growth of 34.1%, Ionis reported a net loss of $-140,480,000.00 on quarterly revenue of $133,814,000.00 and was unprofitable over its most recent full fiscal year, indicating profitability gains have not yet materialized alongside top-line expansion. The confluence of declining stock price, persistent losses despite strong revenue growth, and her significant insider disposition warrants investor scrutiny of the cash runway and path to profitability.

CEO Monia Brett sells 33,445 shares of IONS at $32.63; stock now $31.43, down 39.6% from 52-week high, amid unprofitable operations.

Monia Brett P, Chief Executive Officer, sold 33,445 shares at $32.63 on 2025-01-16, reducing holdings by 13.9% to 207,396 shares. The transaction occurred when IONS traded near the low end of its 52-week range ($31.43–$52.01) and the stock has declined 13.3% over the prior 30 days and 20.8% over 90 days. Notably, Brett's prior five sales at IONS were all well-timed at the 90-day mark, suggesting a consistent pattern of selling ahead of declines at this ticker. The company remains unprofitable with net income of $-140,480,000.00 against revenue of $133,814,000.00 in the latest quarter, even as annual revenue growth reached 34.1%. This combination—a CEO reduction of meaningful holdings coinciding with sharp recent price declines, sustained unprofitability despite strong revenue growth, and a track record of well-timed selling at this company—warrants investor attention to the company's path to profitability and cash burn dynamics.